Updates on Rheumatoid Arthritis: From Diagnosis to Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".
Deadline for manuscript submissions: 25 February 2025 | Viewed by 42
Special Issue Editor
Interests: pharmacoepidemiology; pharmacovigilance; effectiveness; post-marketing drug safety evaluation; observational studies; systematic review; meta-analysis; rheumatoid arthritis
Special Issue Information
Dear Colleagues,
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease, causing symmetrical polyarthritis, typically resulting in swollen, stiff and painful joints. This condition affects approximatelly 5 in every 1000 adults worldwide. The pharmacological treatment of RA should start as soon as the diagnosis is made. Methotrexate is an effective conventional synthetic (cs) disease-modifying antirheumatic drug (DMARD) and it is the first-line treatment option. If the disease activity remains moderate to high, additional treatment with csDMARDs, biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) should be considered.
New treatments for RA have been introduced over the last few years, like Janus-Kinase (JAK) inhibitors or interleukin-6 (IL-6) inhibitors, which have demonstrated effectiveness in controlling the disease. Nonetheless, safety issues have also been recently identified, delaying or inhibiting the approval of new drugs.
There are agents being currently developed for RA treatment, like those targeting CD40 and CD40 ligand, programmed death protein 1 (PD-1), or granulocyte-macrophage colony-stimulating factor (GM-CSF).
The current Special Issue will focus on updated research addressing the effectiveness and safety of pharmacological alternatives for RA, aiming to improve the knowledge about clinical management and patients’ outcomes in the field.
Dr. Carlos Alves
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- rheumatoid arthritis
- pharmacological intervention
- treatment
- clinical development
- effectiveness
- safety
- immune therapy
- biological disease-modifying antirheumatic drugs (bDMARDs)
- synthetic disease-modifying antirheumatic drugs (sDMARDs)
